Navigation Links
Biothera's Imprime PGG Enhanced Effectiveness of Avastin in Cancer,Study

EAGAN, Minn.--(BUSINESS WIRE)--Jun 4, 2007 - Imprime PGG(TM), an investigational new drug from Biothera that enhances the innate immune system response, increases the effectiveness of Avastin(R) (bevacizumab) to kill cancer cells, according to new preclinical research presented yesterday at the 2007 American Society of Clinical Oncology Annual Meeting in Chicago.

Researchers at the Brown Cancer Center, University of Louisville, Kentucky, studied the synergistic effects of Imprime PGG in combination with Avastin in a xenograft mouse model where human ovarian cancer cells were implanted into the mice. In the treatment group receiving both Imprime PGG and Avastin, 86% of the mice survived 100 days compared with only 43% in the group receiving Avastin alone.

"The combination of Imprime PGG and Avastin should be considered as potential treatment approach in patients with VEGF-expressing tumors and needs to be further investigated in clinical trials," said Carolina Salvador, M.D., a clinical instructor at the Brown Cancer Center.

"The results are consistent with previous research demonstrating improved outcomes for both tumor size and long-term survival when Imprime PGG is combined with complement-activating monoclonal antibodies," said Daniel K. Conners, president of Biothera's Pharmaceutical Group. "Our technology has the potential to dramatically enhance both existing and developmental drug treatments for most major types of cancer."

The ASCO poster presentation is entitled, "Cytotoxicity of Bevacizumab is Enhanced by Beta-glucan in Tumors Expressing Membrane-Bound VEGF." Dr. Salvador conducted the research in collaboration with Jun Yan, MD, Ph.D., the lead researcher at the Tumor Immunobiology Program at the Brown Cancer Center.

About Imprime PGG(TM)

Imprime PGG is a biological response modifier that enhances specific innate immune cell responses. Biothera has completed two Phas e I clinical trials under its cancer Investigational New Drug (IND) application for the use of Imprime PGG in combination with anti-cancer monoclonal antibodies. Under a separate IND, the company also has completed a Phase I/II trial with Imprime PGG in combination with a hematopoietic growth factor.

Biothera plans to initiate multiple Phase Ib and Phase II studies with Imprime PGG in combination with anti-cancer monoclonal antibodies.

About Avastin(R)

Avastin is the first U.S. Food and Drug Administration (FDA) approved therapy designed to inhibit angiogenesis, the process by which new blood vessels develop and carry vital nutrients to a tumor. Avastin is approved, in combination with intravenous 5-fluorouracil-based (5-FU) chemotherapy, for first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum and in combination with carboplatin and paclitaxel for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC). Avastin is a product of Genentech.

About Biothera, the Immune Health Company

Biothera is a biotechnology company dedicated to improving immune health. The company's primary focus is developing pharmaceuticals that engage the innate immune system to fight cancer. Other applications include hematopoiesis (production of blood cells) and infectious disease. In addition, Biothera manufactures and markets food-grade ingredients that support healthy immune function to the nutritional supplement, functional food, cosmetic and animal nutrition markets. Website: www.biotherapharma.com.

Contact

Biothera, the Immune Health Company
David Walsh, 651-256-4606
VP, Communications
dwalsh@biotherapharma.com


'"/>




Related medicine technology :

1. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
2. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
3. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
4. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
5. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
6. St. Jude Study Shows Effectiveness of Peramivir in Prevention of Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection
7. Study Supports Cost-Effectiveness of Medtronics Spasticity Treatment for Children with Cerebral Palsy
8. FDA MedWatch: Avastin (bevacizumab) and Formation of Tracheoesophageal Fistula in a Recent Clinical Study in Patients with Limited-stage Small Cell Lung Cancer
9. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
10. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):